News

(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Benjamin Garmezy discussing a phase 1 trial of mevrometostat (PF-06821497), a potent and ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Session State of the Art Lecture: Personalizing treatment for patients with ...
The initial insertion of a suprapubic catheter (SPC), a procedure referred to as a suprapubic cystostomy, can be performed under local or general anesthesia with a trocar system, using cystoscopic or ...
(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Scott T. Tagawa discussing ProstACT Global, a phase 3 study of 177 ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.
ASCO 2025 results of AREN1721, phase 2 trial of axitinib + nivolumab combination therapy, nivolumab, TFE/translocation RCC, COG-led NCTN phase 2 trial of nivolumab + axitinib.
(UroToday.com) The 2025 PSMA and Beyond annual meeting featured a PSMA session and a presentation by Dr. Amir Iravani discussing the landscape of approved PSMA imaging agents. Over the last several ...
ASCO 2025, Clear Cell Renal Cell Carcinoma (ccRCC), tumor necrosis factor (TNF), ADI-270, Armored Allogeneic Anti-CD70, Chimeric Antigen Receptor γδ, T Cell Therapy.
Oral presentation selected for Best of ASCO 2025 in recognition of quality, rigor, and impact First validated algorithm to identify high-risk non-metastatic prostate cancer patients most likely to ...
(UroToday.com) The 2025 European Association of Urology (EAU) Annual Congress held in Madrid, Spain was host to a plenary session on organ-sparing paradigms in kidney and bladder cancer. Dr. Peter ...
ASCO 2025, Prostate Cancer, androgen deprivation therapy (ADT), HSV-tk gene, Prodrug, intraprostatic injections of CAN-2409, CAN-2409, CAN-2409 plus Prodrug, External Beam Radiation for Newly ...